78553-51-2

Basic information

• Product Name: CBZ-ALPHA-ALLYL-L-GLY
• Synonyms: N-ALPHA-CARBOBENZOXY-L-ALPHA-ALLYL-GLYCINE;RARECHEM AL CF 0941;Z-ALGLY-OH;A-(ALLYL)GLY-OH;CBZ-(S)-2-AMINO-4-PENTENOIC ACID;CBZ-ALPHA-ALLYL-L-GLY;(S)-2-CBZ-AMINO-4-PENTENOIC ACID;L-CBZ-ALLYLGLYCINE
• CAS NO: 78553-51-2
• Molecular Formula: C₁₃H₁₅NO₄
• Molecular Weight: 249.26
• Mol File: 78553-51-2.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: CBZ-ALPHA-ALLYL-L-GLY(CAS DataBase Reference)
• NIST Chemistry Reference: CBZ-ALPHA-ALLYL-L-GLY(78553-51-2)
• EPA Substance Registry System: CBZ-ALPHA-ALLYL-L-GLY(78553-51-2)

Safety Data

• Hazardous Substances Data: 78553-51-2(Hazardous Substances Data)

Usage

Uses

(2S)-2-[[(phenylmethoxy)carbonyl]amino]-4-Pentenoic acid is a useful building block, and has been used in the regioselective preparation of nonracemic silylated amino acids.

Upstream product

• 127862-74-2 2-Benzyloxycarbonylamino-pent-4-enoic acid 2,2,2-trifluoro-ethyl ester 
• 50299-14-4 N-Acetyl-α-allylglycine 
• 501-53-1 benzyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 16338-48-0 L-allylglycine 
• 26054-60-4 ((S)-2-Oxo-oxetan-3-yl)-carbamic acid benzyl ester 
• 3536-96-7 vinylmagnesium chloride 

Downstream Products

• 78553-49-8 tert-butyl (S)-2-(benzyloxycarbonylamino)pent-4-enoate 
• 391594-67-5 dimethyl (2RS,6S)-2-hydroxy-6-[N-(benzyloxycarbonyl)-amino]heptane-1,7-dioate 
• 178859-58-0 (S)-2-Benzyloxycarbonylamino-6-oxo-heptanedioic acid dimethyl ester 
• 178859-61-5 (S)-2-Oxo-6-(3-phenyl-propionylamino)-heptanedioic acid dimethyl ester 
• 178859-60-4 (S)-2-Oxo-6-[(E)-(3-phenyl-acryloyl)amino]-heptanedioic acid dimethyl ester 

Relevant articles and documents

MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.

Divergent Access to Histone Deacetylase Inhibitory Cyclopeptides via a Late-Stage Cyclopropane Ring Cleavage Strategy. Short Synthesis of Chlamydocin

A unified step-economical strategy for accessing histone deacetylase inhibitory peptides is proposed, based on the late-stage installation of multiple zinc-binding functionalities via the cleavage of the strained cyclopropane ring in the common pluripoten

CONFORMATIONALLY CONSTRAINED, SYNTHETIC MACROCYCLIC COMPOUNDS

PROBLEM TO BE SOLVED: To provide a novel macrocyclic compound showing agonistic or antagonistic activity on a motilin receptor, a serotonin receptor and a prostaglandin F2A receptor. SOLUTION: This invention provides a macrocyclic compound incorporating building blocks A, B and C, represented by formula (I). The compound is useful for the treatment of motility disorders of the gastrointestinal tract, CNS-related disease and ocular hypertension. COPYRIGHT: (C)2015,JPO&INPIT